New analysis showed dose adjustment of Gilotrif ® (afatinib) improved tolerability without an apparent impact on efficacy in patients with EGFR mutation-positive non-small cell lung cancer

Source: Boehringer Ingelheim Press Releases - Category: Research Source Type: news